Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction

Clinical Therapeutics

Volumn 30, Issue PART 2, 2008, Pages 2217-2227

  Sun, Shawn X ^a   Ye, Xiaolan ^a   Lee, Kwan Y ^a   Dupclay Jr , Leon ^b   Plauschinat, Craig ^b  

^a Walgreens Health Services   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

adherence; cardiovascular related costs; compliance; heart failure; myocardial infarction; persistence; rehospitalization; total health care costs

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PATIENT SAFETY; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT READMISSION; RETROSPECTIVE STUDIES;

EID: 61549139791     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.005     Document Type: Article

References (27)

1. Thom T., Haase N., Rosamond W., et al. Heart Disease and Stroke Statistics-2006 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (October 30, 2008). http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.105.171600vl
2. Weintraub W.S., Kawabata H., Tran M., et al. Cost of heart failure in patients receiving beta-blockers and angiotensinconverting enzyme inhibitors. Clin Drug Investig 24 (2004) 255-264
3. Fonarow G.C., Abraham W.T., Albert N.M., et al., for the OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297 (2007) 61-70
4. Smith Jr. S.C., Allen J., Blair S.N., et al., for the AHA/ACC; and the National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. [published correction appears in Circulation. 2006;113:e847]. Circulation 113 (2006) 2363-2372
5. Smith N.L., Chan J.D., Rea T.D., et al. Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. Am Heart J 148 (2004) 710-717
6. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) (2001). http://www.acc.org/clinical/guidelines/failure/hfindex.htm Accessed October 30, 2008
7. Shaya F.T., El Khoury A.C., Mullins C.D., et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 12 (2006) 313-319
8. Tu W., Morris A.B., Li J., et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 77 (2005) 189-201
9. Cole J.A., Norman H., Weatherby L.B., and Walker A.M. Drug copayment and adherence in chronic heart failure: Effect on cost and outcomes. Pharmacotherapy 26 (2006) 1157-1164
10. Rasmussen J.N., Chong A., and Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297 (2007) 177-186
11. Balkrishnan R., Norwood G.J., and Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Ther 20 (1998) 567-580
12. McCombs J.S., Nichol M.B., Stimmel G.L., et al. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 51 Suppl (1990) 60-69
13. Gotto Jr. A.M., and Grundy S.M. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial data: Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council meeting. Circulation 99 (1999) E1-E7
14. Lichtenberg F.R. Do (more and better) drugs keep people out of hospitals?. Am Econ Rev 86 (1996) 384-388
15. Sokol M.C., McGuigan K.A., Verbrugge R.R., and Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43 (2005) 521-530
16. International Classification of Diseases. Ninth Revision (2002), St. Anthony Publishing/Medicode, Salt Lake City, UT Clinical Modification
17. Gilmer T.P., Dolder C.R., Lacro J.P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psych 161 (2004) 692-699
18. Sun S.X., Liu G.G., Christensen D.B., and Fu A.Z. Review and analysis of hospitalization costs associated with antipsy chotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 23 (2007) 2305-2312
19. Erkens J.A., Panneman M.M., Klungel O.H., et al. Differences in antihypertensive drug persistence associated with drug class and gender: A PHARMO study. Pharmacoepidemiol Drug Saf 14 (2005) 795-803
20. Peterson A.M., Nau D.P., Cramer J.A., et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10 (2007) 3-12
21. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
22. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
23. Diehr P., Yanez D., Ash A., et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 20 (1999) 125-144
24. Blough D.K., Madden C.W., and Hornbrook M.C. Modeling risk using generalized linear models. J Health Econ 18 (1999) 153-171
25. Bouckaert A., and Crott R. The difference in mean costs as a pharmacoeconomic outcome variable: Power considerations. Control Clin Trials 18 (1997) 58-64
26. Liu G.G., Sun S.X., Christensen D.B., and Zhao Z. Cost analysis of schizophrenia treatment with second generation antipsychotic medications in North Carolina's Medicaid program. J Am Pharm Assoc (2003) 47 (2007) 77-81
27. Cabana M.D., Rand C.S., Powe N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999) 1458-1465